ABO and Alzheimer disease: To further confirm Mertk's contribution to the early stage of AD, we manipulated Aβo-induced and 3xTg-AD mouse models with Mertk knockout or inhibition before plaque formation, resulting in reduced microglial synaptic elimination and improved behavioral outcomes.